Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 4, Pages 320
Publisher
MDPI AG
Online
2019-04-05
DOI
10.3390/cells8040320
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutational burden of resectable pancreatic cancer, as determined by whole transcriptome and whole exome sequencing, predicts a poor prognosis
- (2018) Elisa Grassi et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
- (2018) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model
- (2018) Heng Sheng Sow et al. INTERNATIONAL JOURNAL OF CANCER
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer
- (2018) Daniel R Principe et al. MOLECULAR CANCER THERAPEUTICS
- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses
- (2017) Joanne E. Konkel et al. IMMUNITY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Biological Role and Therapeutic Targeting of TGF-β 3 in Glioblastoma
- (2017) Katharina Seystahl et al. MOLECULAR CANCER THERAPEUTICS
- Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
- (2017) Shomyseh Sanjabi et al. Cold Spring Harbor Perspectives in Biology
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
- (2017) Masaki Terabe et al. OncoImmunology
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- TGF Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis
- (2016) D. R. Principe et al. CANCER RESEARCH
- Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors
- (2016) Julius Strauss et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia
- (2016) Yong Wu et al. Oncotarget
- TGF-β1 contributes to CD8+ Treg induction through p38 MAPK signaling in ovarian cancer microenvironment
- (2016) Meng Wu et al. Oncotarget
- Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
- (2015) Yutaka Fujiwara et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- MDSC and TGF Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes
- (2015) A. A. Shvedova et al. CANCER RESEARCH
- Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
- (2015) PANAGIOTIS PAPAGEORGIS et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance
- (2015) Izabela Winkler et al. Journal of Ovarian Research
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia
- (2014) Florencia McAllister et al. CANCER CELL
- TGFβ: A player on multiple fronts in the tumor microenvironment
- (2014) Fabian Caja et al. Journal of Immunotoxicology
- TGF- : Duality of Function Between Tumor Prevention and Carcinogenesis
- (2014) D. R. Principe et al. JNCI-Journal of the National Cancer Institute
- FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units
- (2014) et al. LABORATORY ANIMALS
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
- (2014) Mahesh Yadav et al. NATURE
- Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
- (2014) Jing Lu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: Connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production
- (2012) Carmela Guido et al. CELL CYCLE
- Cellular and molecular basis for the regulation of inflammation by TGF-
- (2010) A. Yoshimura et al. JOURNAL OF BIOCHEMISTRY
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β
- (2009) Hae-Young Park et al. Immune Network
- Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
- (2008) Li Yang et al. CANCER CELL
- TGF-β: A Master of All T Cell Trades
- (2008) Ming O. Li et al. CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now